Safety

Safety—
first-line
treatment

JUPITER-02 SAFETY


LOQTORZI™ adverse reactions1

Adverse reactions (≥10%) in patients with R/M NPC who received LOQTORZI™ + chemotherapy in JUPITER-02

PINCH TO ENLARGE
All grades (%)Grade 3 or 4 (%)04.20.7842.8662.14602300.763017028132.82.8800.72.800.703.50.72.10.7n=143Placebo + chemo8Grade 3 or 4 (%)2413173127725206222223Adverse reaction*#NauseaVomitingConstipationDiarrheaStomatitis§Decreased appetiteHypothyroidism||RashMusculoskeletalpain‡‡ PyrexiaEpistaxisInsomniaPeripheral neuropathy**Cough††Pneumonia|||| MalaiseHypertension¶¶ DizzinessFatigue#Headache§§PruritusUpper respiratoryinfection§§All grades (%)3901.471682.11.4311200.7383.4 3.4 3623170 321023302618251.41.30001102110210.76019180.700.755n=146LOQTORZI™ + chemoGastrointestinal disordersMetabolism and nutrition disordersEndocrine disordersSkin disordersGeneral disordersNervous systemdisordersRespiratory, thoracic, and mediastinal disordersMusculoskeletaldisordersInfectionsPsychiatricdisordersVascular disordersGastrointestinal disordersMetabolism and nutrition disordersEndocrine disordersGeneral disordersNervous systemdisordersRespiratory, thoracic, and mediastinal disordersMusculoskeletaldisordersPsychiatricdisordersVascular disordersInfectionsSkin disorders
*National Cancer Institute Common Terminology Criteria for Adverse Events v5.0.1
Patients were treated with LOQTORZI™ + cisplatin and gemcitabine for up to six 21-day cycles followed by LOQTORZI™ monotherapy.1
Patients were treated with placebo + cisplatin and gemcitabine for up to six 21-day cycles followed by placebo monotherapy.1
§Includes mouth ulceration, stomatitis, and radiation stomatitis.1
||Includes hypothyroidism, triiodothyronine decreased, triiodothyronine free decreased, and thyroiditis.1
Includes acneiform dermatitis, allergic dermatitis, catheter-site rash, dermatitis, drug eruption, eczema, erythema, macule, maculopapular rash, palmar-plantar erythrodysesthesia syndrome, papule, pruritic rash, rash, and urticaria.1
#Includes asthenia and fatigue.1
**Includes hypoesthesia, neuralgia, neuropathy peripheral, paresthesia, and peripheral sensory neuropathy.1
††Includes cough and productive cough.1
‡‡Includes back pain, bone pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain, pain in extremity, pain in jaw.1
§§Includes acute sinusitis, bronchitis, laryngitis, nasopharyngitis, pharyngitis, respiratory tract infection, rhinitis, sinusitis, and upper respiratory tract infection.1
||||Includes aspiration pneumonia and pneumonia.1
¶¶Includes blood pressure increased, blood pressure systolic increased, hypertension, and hypertensive crisis.1
Serious and fatal adverse reactions
  • Serious adverse reactions occurred in 43% of patients receiving LOQTORZI™ in combination with cisplatin and gemcitabine
    • Serious adverse reactions in ≥2% were thrombocytopenia (14%), neutrophil count decreased (10%), pneumonia (10%), anemia (9%), abnormal hepatic function (2.7%), and rash (2.1%)
  • Of the patients who received LOQTORZI™ in combination with cisplatin and gemcitabine, there were 3 fatal adverse reactions (2.1%): 1 due to epistaxis; 1 due to intracranial hemorrhage associated with immune-related thrombocytopenia and coagulopathy, and 1 due to pneumonia
Discontinuations and dosage interruptions
  • Permanent discontinuation of LOQTORZI™, when given in combination with cisplatin and gemcitabine, due to an adverse reaction occurred in 12% of patients
    • Adverse reactions resulting in permanent discontinuation of LOQTORZI™ in ≥1% of patients were pneumonia (2.1%), pulmonary tuberculosis (1.4%), rash (1.4%), and vomiting (1.4%)
  • Dosage interruptions of LOQTORZI™ due to an adverse reaction occurred in 50% of patients
    • Adverse reactions which required dosage interruption in ≥2% were anemia (17%), decreased neutrophils (12%), thrombocytopenia (12%), acute kidney injury (4.1%), pneumonia (6%), fatigue (2.7%), upper respiratory infection (2.7%), and hypothyroidism (2.1%)

JUPITER-02 laboratory abnormalities

Select laboratory abnormalities (≥20%) that worsened from baseline in patients with R/M NPC who received LOQTORZI™ in combination with cisplatin and gemcitabine in JUPITER-02

PINCH TO ENLARGE
All grades (%)Grade 3 or 4 (%)9777483541169562463988506653352738800.7006364.28493.5314.900Grade 3 or 4 (%)Laboratory abnormalities###Decreased hemoglobinDecreased magnesiumDecreased albuminIncreased calciumIncreased creatinineDecreased glucoseDecreased neutrophilsDecreased sodiumDecreased calciumDecreased potassiumDecreased lymphocytesIncreased alanine aminotransfer-aseDecreased plateletsIncreased aspartate aminotransfer-aseIncreased lactate dehydrogena-seIncreased alkaline phosphatase§§All grades‡‡‡(%)504.2000.71.45893.510576332.70094784939392391634540885871584227LOQTORZI™ + chemo***Placebo + chemo†††HematologyChemistry
##Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: LOQTORZI™/chemotherapy (range: 139 to 146 patients) and placebo/chemotherapy (range: 136 to 143 patients).1
***Patients were treated with LOQTORZI™ + cisplatin and gemcitabine for up to six 21-day cycles followed by LOQTORZI™ monotherapy.1
†††Patients were treated with placebo + cisplatin and gemcitabine for up to six 21-day cycles followed by placebo monotherapy.1
‡‡‡Graded per National Cancer Institute Common Terminology Criteria for Adverse Events v5.0.1
R/M NPC=recurrent locally advanced/metastatic nasopharyngeal carcinoma.
Reference: 1. LOQTORZI™ (toripalimab-tpzi) Prescribing Information. Redwood City, CA: Coherus BioSciences, Inc.
 
This module offers you quick
access to key information
about LOQTORZI™ to help you
support your patients.
Explore LOQTORZI™ data
in the interactive
Prescribing Information.
Register to receive the latest
information and announcements
about LOQTORZI™.
Important Safety Information
Severe and Fatal Immune-Mediated Adverse Reactions
Immune-mediated adverse reactions listed herein may not include all possible severe and fatal immune-mediated adverse reactions. Immune-mediated adverse reactions, which can be severe or fatal, occur in any organ system or tissue, affect more than one body system simultaneously, and occur at any time after starting PD-1/PD-L1 blocking antibody. While immune-mediated adverse reactions usually manifest during treatment, they can also manifest after discontinuation of PD-1/PD-L1 blocking antibodies.
SELECT IMPORTANT SAFETY INFORMATION
LOQTORZI™ is associated with the following Warnings and Precautions: severe and fatal immune-mediated adverse reactions including pneumonitis, colitis, hepatitis and hepatotoxicity, endocrinopathies, nephritis with renal dysfunction, dermatologic adverse reactions, other immune-mediated adverse reactions; infusion-related reactions; complications of allogeneic hematopoietic stem cell transplantation (HSCT); and embryo-fetal toxicity. Please see detailed Important Safety Information.
INDICATIONS
LOQTORZI™ (toripalimab-tpzi) is indicated:
  • In combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC).
  • As a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.

Immune-mediated adverse reactions listed herein may not include all possible severe and fatal immune-mediated adverse reactions.
Immune-mediated adverse reactions, which can be severe or fatal, occur in any organ system or tissue and occur at any time after starting PD-1/PD-L1 blocking antibody. While immune-mediated adverse reactions usually manifest during treatment they can also manifest after discontinuation of PD-1/PD-L1 blocking antibodies.

  • Monitor for early identification and management. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.
  • Withhold or permanently discontinue LOQTORZI™ based on severity and type of reaction (see Dosage and Administration in Prescribing Information). In general, if LOQTORZI™ requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.

Immune-Mediated Pneumonitis

LOQTORZI™ can cause immune-mediated pneumonitis.

  • In patients receiving LOQTORZI™ in combination with cisplatin and gemcitabine, immune-mediated pneumonitis occurred in 2.1% (3/146) of patients, including Grade 2 (1.4%) adverse reactions. Pneumonitis resolved in 67% (2/3) of these patients.
  • In patients receiving LOQTORZI™ monotherapy, immune-mediated pneumonitis occurred in 2.6% (22/851) of patients, including fatal (0.2%), Grade 3 (0.7%), and Grade 2 (1.1%) adverse reactions. Systemic corticosteroids were required in 82% (18/22) of patients with pneumonitis. Pneumonitis led to permanent discontinuation of LOQTORZI™ in 1.2% (10/851) of patients. Pneumonitis resolved in 23% (5/22) of these patients.
Important Safety Information
Severe and Fatal Immune-Mediated Adverse Reactions
Immune-mediated adverse reactions listed herein may not include all possible severe and fatal immune-mediated adverse reactions. Immune-mediated adverse reactions, which can be severe or fatal, occur in any organ system or tissue, affect more than one body system simultaneously, and occur at any time after starting PD-1/PD-L1 blocking antibody. While immune-mediated adverse reactions usually manifest during treatment, they can also manifest after discontinuation of PD-1/PD-L1 blocking antibodies.
SELECT IMPORTANT SAFETY INFORMATION
LOQTORZI™ is associated with the following Warnings and Precautions: severe and fatal immune-mediated adverse reactions including pneumonitis, colitis, hepatitis and hepatotoxicity, endocrinopathies, nephritis with renal dysfunction, dermatologic adverse reactions, other immune-mediated adverse reactions; infusion-related reactions; complications of allogeneic hematopoietic stem cell transplantation (HSCT); and embryo-fetal toxicity. Please see detailed Important Safety Information.
INDICATIONS
LOQTORZI™ (toripalimab-tpzi) is indicated:
  • In combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC).
  • As a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.

Immune-mediated adverse reactions listed herein may not include all possible severe and fatal immune-mediated adverse reactions.
Immune-mediated adverse reactions, which can be severe or fatal, occur in any organ system or tissue and occur at any time after starting PD-1/PD-L1 blocking antibody. While immune-mediated adverse reactions usually manifest during treatment they can also manifest after discontinuation of PD-1/PD-L1 blocking antibodies.

  • Monitor for early identification and management. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.
  • Withhold or permanently discontinue LOQTORZI™ based on severity and type of reaction (see Dosage and Administration in Prescribing Information). In general, if LOQTORZI™ requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.

Immune-Mediated Pneumonitis

LOQTORZI™ can cause immune-mediated pneumonitis.

  • In patients receiving LOQTORZI™ in combination with cisplatin and gemcitabine, immune-mediated pneumonitis occurred in 2.1% (3/146) of patients, including Grade 2 (1.4%) adverse reactions. Pneumonitis resolved in 67% (2/3) of these patients.
  • In patients receiving LOQTORZI™ monotherapy, immune-mediated pneumonitis occurred in 2.6% (22/851) of patients, including fatal (0.2%), Grade 3 (0.7%), and Grade 2 (1.1%) adverse reactions. Systemic corticosteroids were required in 82% (18/22) of patients with pneumonitis. Pneumonitis led to permanent discontinuation of LOQTORZI™ in 1.2% (10/851) of patients. Pneumonitis resolved in 23% (5/22) of these patients.

Immune-Mediated Colitis

LOQTORZI™ can cause immune-mediated colitis, which may present with diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. In patients receiving LOQTORZI™ monotherapy, immune-mediated colitis occurred in 0.4% (3/851) of patients, including Grade 3 (0.2%) and Grade 2 (0.1%) adverse reactions. Colitis resolved in all 3 patients.

Hepatotoxicity and Immune-Mediated Hepatitis

LOQTORZI™ can cause immune-mediated hepatitis.

  • In patients receiving LOQTORZI™ in combination with cisplatin and gemcitabine, immune-mediated hepatitis occurred in 0.7% (1/146) of patients, which was a Grade 3 (0.7%) adverse reaction. The patient with immune-mediated hepatitis required systemic corticosteroids.
  • In patients receiving LOQTORZI™ monotherapy, immune-mediated hepatitis occurred in 3.3% (28/851) of patients, including Grade 4 (0.8%), Grade 3 (2.1%), and Grade 2 (0.4%) adverse reactions. Hepatitis led to permanent discontinuation of LOQTORZI™ in 1.1% of patients and withholding of LOQTORZI™ in 0.8% of patients. Hepatitis resolved in 54% (15/28) of these patients.

Immune-Mediated Endocrinopathies

Adrenal Insufficiency

LOQTORZI™ can cause primary or secondary adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold or permanently discontinue LOQTORZI™ depending on severity. In patients receiving LOQTORZI™ monotherapy, adrenal insufficiency occurred in 0.5% (4/851) of patients, including Grade 2 (0.4%) and Grade 1 (0.1%) adverse reactions. Systemic corticosteroids were required in 75% (3/4) of the patients with adrenal insufficiency. Adrenal insufficiency led to withholding of LOQTORZI™ in 0.1% (1/851) of patients. In the one patient in whom LOQTORZI™ was withheld, LOQTORZI™ was reinitiated after symptom improvement.

Hypophysitis

LOQTORZI™ can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effects such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as indicated. Withhold or permanently discontinue LOQTORZI™ depending on severity. In patients receiving LOQTORZI™ monotherapy, hypophysitis occurred in 0.4% (3/851) of patients receiving LOQTORZI™, including Grade 3 (0.2%) and Grade 2 (0.1%) adverse reactions. All three patients received systemic corticosteroids. Hypophysitis led to permanent discontinuation of LOQTORZI™ in 0.1% (1/851) of patients and withholding of LOQTORZI™ in 0.1% (1/851) of patients. The one patient in whom LOQTORZI™ was withheld reinitiated LOQTORZI™.

Thyroid Disorders

LOQTORZI™ can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue LOQTORZI™ depending on severity.

  • In patients receiving LOQTORZI™ in combination with cisplatin and gemcitabine, thyroiditis occurred in 2.1% (3/146) of patients receiving LOQTORZI™, including Grade 2 (1.4%). Three patients required thyroid hormone replacement therapy. Thyroiditis resolved in one of the 3 patients. Hyperthyroidism occurred in 1.4% (2/146) of patients receiving LOQTORZI™ in combination with cisplatin and gemcitabine. Hyperthyroidism resolved in these 2 patients. Hypothyroidism occurred in 30% (44/146) of patients receiving LOQTORZI™ in combination with cisplatin and gemcitabine, including Grade 2 (24%) and Grade 1 (6%). Eighty percent of the 44 patients required thyroid hormone replacement therapy. LOQTORZI™ was withheld in 2.1% (3/146) of the patients. Of the 3 patients in whom LOQTORZI™ was withheld, 2 patients reinitiated LOQTORZI™.
  • In patients receiving LOQTORZI™ monotherapy, thyroiditis occurred in 0.6% (5/851) patients receiving LOQTORZI™, including Grade 2 (0.1%). Two of these 5 patients received systemic corticosteroids and 2 required thyroid hormone replacement therapy. Thyroiditis resolved in 2 of the 5 patients. Hyperthyroidism occurred in 7% (55/851) of patients receiving LOQTORZI™, including Grade 2 (1.9%). Hyperthyroidism resolved in 85% (47/55) of the patients. Hypothyroidism occurred in 15% (128/851) of patients receiving LOQTORZI™, including Grade 2 (8%). Sixty three percent of the 128 patients required thyroid hormone replacement therapy. LOQTORZI™ was withheld in 0.5% of patients. Of the 4 patients in whom LOQTORZI™ was withheld, 3 patients reinitiated LOQTORZI™.

Type 1 Diabetes Mellitus, which can present with Diabetic Ketoacidosis

Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold or permanently discontinue LOQTORZI™ depending on severity. In patients receiving LOQTORZI™ monotherapy, diabetes mellitus occurred in 0.9% (8/851) of patients receiving LOQTORZI™, including Grade 4 (0.1%), Grade 3 (0.7%), and Grade 2 (0.1%). Diabetes mellitus led to permanent discontinuation in 0.4% of patients. Six of the 8 (75%) patients with diabetes mellitus required long-term insulin therapy.

Immune-Mediated Nephritis with Renal Dysfunction

LOQTORZI™ can cause immune-mediated nephritis.

  • In patients receiving LOQTORZI™ in combination with cisplatin and gemcitabine, immune-mediated nephritis occurred in 0.7% (1/146) of patients receiving LOQTORZI™. The one patient with immune-mediated nephritis (Grade 4) required systemic corticosteroids and nephritis led to discontinuation of LOQTORZI™. Nephritis resolved in this patient.
  • In patients receiving LOQTORZI™ monotherapy, immune-mediated nephritis occurred in 0.5% (4/851) of patients, including Grade 3 (0.5%) adverse reactions. Nephritis resolved in 75% (3/4) of these patients.

Immune-Mediated Dermatologic Adverse Reactions

LOQTORZI™ can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson Syndrome (SJS), drug rash with eosinophilia and systemic symptoms (DRESS), and toxic epidermal necrolysis (TEN), has occurred with PD-1/PD-L1 blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-exfoliative rashes. Withhold or permanently discontinue LOQTORZI™ depending on severity.

  • In patients receiving LOQTORZI™ in combination with cisplatin and gemcitabine, immune-mediated dermatologic adverse reactions occurred in 8% (12/146) of patients, including Grade 3 (3.4%) and Grade 2 (1.4%) adverse reactions. Systemic corticosteroids were required in 25% (3/12) of the patients with immune-mediated dermatologic adverse reactions. Immune-mediated dermatologic adverse reactions led to permanent discontinuation of LOQTORZI™ in 2.1% (3) of patients. Immune-mediated dermatologic adverse reactions resolved in 92% (11/12) of these patients.
  • In patients receiving LOQTORZI™ monotherapy, immune-mediated dermatologic adverse reactions occurred in 4% (34/851) of patients, including Grade 3 (0.4%) and Grade 2 (1.4%) adverse reactions. Immune-mediated dermatologic adverse reactions led to withholding of LOQTORZI™ in 0.4% (3) of the patients. Systemic corticosteroids were required in 12% (4/34) of the patients with immune-mediated dermatologic adverse reactions. Immune-mediated dermatologic adverse reactions resolved in 71% (24/34) of these patients.

Other Immune-Mediated Adverse Reactions

The following clinically significant immune-mediated adverse reactions occurred at an incidence of <1% (unless otherwise noted) in patients who received LOQTORZI™ or were reported with the use of other PD-1/PD-L1 blocking antibodies. Severe or fatal cases have been reported for some of these adverse reactions.

  • Cardiac/Vascular: Myocarditis, pericarditis, vasculitis, pericardial effusion
  • Nervous System: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy
  • Ocular: Uveitis, iritis and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss.
  • Gastrointestinal: Pancreatitis, to include increases in serum amylase and lipase levels, gastritis, duodenitis
  • Musculoskeletal and Connective Tissue: Myositis/polymyositis, rhabdomyolysis (and associated sequelae, including renal failure), arthritis, polymyalgia rheumatica, dermatomyositis
  • Endocrine: Hypoparathyroidism
  • Hematologic/Immune: Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection

Infusion-related reactions

LOQTORZI™ can cause severe or life-threatening infusion-related reactions including hypersensitivity and anaphylaxis.

  • In patients receiving LOQTORZI™ in combination with cisplatin and gemcitabine, infusion-related reactions have been reported in 4.1% of patients, including Grade 2 (0.7%) reactions.
  • In patients receiving LOQTORZI™ monotherapy, infusion-related reactions occurred in 2% of 851 patients, including Grade 3 (0.1%) and Grade 2 (0.6%). LOQTORZI™ was withheld for one Grade 3 infusion related reaction. Monitor patients for signs and symptoms of infusion-related reactions including rigors, chills, wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever. Interrupt or slow the rate of infusion for mild (Grade 1) or moderate (Grade 2) infusion-related reactions. For severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions, stop infusion and permanently discontinue LOQTORZI™.

Complications of allogeneic HSCT

Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1 blocking antibody. Transplant-related complications include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/PD-L1 blocking antibody prior to or after an allogeneic HSCT.

Embryo-fetal toxicity

LOQTORZI™ can cause fetal harm when administered to a pregnant woman. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death. Advise women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with LOQTORZI™ and for 4 months after the last dose.

Lactation

There are no data on the presence of toripalimab-tpzi in human milk; its effects on the breastfed child, or on milk production. Maternal IgG is known to be present in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed child to toripalimab-tpzi are unknown. Because of the potential for serious adverse reactions in breastfed children, advise lactating women not to breastfeed during treatment with LOQTORZI™ and for 4 months after the last dose.

Serious Adverse Reactions

  • In JUPITER-02, when LOQTORZI™ was administered in combination with cisplatin and gemcitabine for the first-line treatment of recurrent, locally advanced or metastatic nasopharyngeal carcinoma, serious adverse reactions occurred in 43% of patients. Serious adverse drug reactions in ≥2% were thrombocytopenia (14%), neutrophil count decreased (10%), pneumonia (10%), anemia (9%), abnormal hepatic function (2.7%), and rash (2.1%). There were three fatal adverse reactions (2.1%): one due to epistaxis; one due to intracranial hemorrhage associated with immune-related thrombocytopenia and coagulopathy; and one due to pneumonia. Permanent discontinuation of LOQTORZI™, due to an adverse reaction occurred in 12% of patients. Adverse reactions resulting in permanent discontinuation of LOQTORZI™ in ≥1% were pneumonia (2.1%), pulmonary tuberculosis (1.4%), rash (1.4%), and vomiting (1.4%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased neutrophils (58%), decreased lymphocytes (57%), decreased hemoglobin (50%) decreased platelets (33%), decreased potassium (10%), decreased sodium (9%), increased alanine aminotransferase (6%), increased or decreased magnesium (4.2% each), decreased calcium (3.5%), increased aspartate aminotransferase (2.7%), increased bilirubin (2.1%).
  • In POLARIS-02, when LOQTORZI™ was administered as a single agent to patients with previously treated, unresectable or metastatic nasopharyngeal carcinoma, serious adverse reactions occurred in 24% of patients. Serious adverse drug reactions in ≥2% were pneumonia (4.7%), abnormal hepatic function (2.6%), and hyperbilirubinemia (2.1%). Fatal adverse reactions occurred in 3.7% of patients who received LOQTORZI™, including death not otherwise specified (1.6%), tumor hemorrhage (0.5%), hepatic failure and thrombocytopenia (0.5%), hyponatremia (0.5%), and sudden death (0.5%). Permanent discontinuation of LOQTORZI™ due to an adverse reaction occurred in 9% of patients. Adverse reaction resulting in permanent discontinuation of LOQTORZI™ in ≥1% included pneumonia (1.1%), abnormal hepatic function (1.1%), and hyperbilirubinemia (1.1%). The most common Grade 3 or 4 laboratory abnormalities (≥2%), were decreased sodium (11%), decreased lymphocytes (9%), decreased hemoglobin (6%), increased aspartate aminotransferase (3.8%), decreased phosphate (3.2%), and increased alkaline phosphatase (2.2%).

Common Adverse Reactions

  • In JUPITER-02, the most common adverse reactions (≥20%) were nausea (71%), vomiting (68%), decreased appetite (55%), constipation (39%), hypothyroidism (38%), rash (36%), pyrexia (32%), diarrhea (31%), peripheral neuropathy (30%), cough (26%), musculoskeletal pain (25%), upper respiratory infection (23%), insomnia (23%), dizziness (21%), and malaise (21%).
  • In POLARIS-02, in patients with previously treated, unresectable or metastatic nasopharyngeal carcinoma, the most common (≥20%) adverse reactions were hypothyroidism (27%), fatigue (22%), and cough (20%).

Are you a
US healthcare professional?

This information is intended for US healthcare professionals.

NO, I AM NOT